Literature DB >> 6303213

Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

B Kemmerich, H Lode, G Belmega, T Jendroschek, K Borner, P Koeppe.   

Abstract

The pharmacokinetics of cefoperazone, cefotaxime, and moxalactam were compared in a cross-over randomized study in 10 healthy volunteers. Each subject received 1.0 g of the three drugs by bolus intravenous injection over 3 min. Serum and urine concentrations were assayed by a microbiological method and in addition by high-pressure liquid chromatography (HPLC) for cefotaxime in five subjects. Maximal concentrations in serum 5 min after the injection were 163 +/- 40.3 mg/liter for cefoperazone, 86.1 +/- 19.0 mg/liter for cefotaxime, and 95.5 +/- 21.1 mg/liter for moxalactam. After 12 h, 1.2 +/- 1.4 mg of cefoperazone per liter and 1.8 +/- 0.9 mg of moxalactam per liter could still be measured. Eight hours after the administration of cefotaxime, serum concentrations were below the detection limit of 0.3 mg/liter in most subjects. By HPLC analysis, the mean maximal concentration of desacetyl cefotaxime was 16.6 +/- 10.5 mg/liter 5 min after application; the metabolite exceeded the serum concentration of the parent compound after 1 to 2 h. Relevant pharmacokinetic parameters were calculated, using two- and three-compartment models. The terminal half-life was 144.1 +/- 37.3 min for cefoperazone, 76.1 +/- 32.0 min for cefotaxime, and 272.4 +/- 114.1 min for moxalactam. The apparent volume of distribution corresponded to the extracellular volume. Only 25.1 +/- 8% of cefoperazone could be detected in urine compared with 53.3 +/- 8.1% of cefotaxime and 61.0 +/- 9.2% of moxalactam in 24 h. A total of 89.6 +/- 11.4% of the cefotaxime dose could be recovered by HPLC in urine, 60.6 +/- 7.7% as cefotaxime and 29.1 +/- 7.0% as desacetyl cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303213      PMCID: PMC184665          DOI: 10.1128/AAC.23.3.429

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

2.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Microbiological studies on cefoperazone.

Authors:  F H Kayser
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

8.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

10.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

View more
  14 in total

1.  Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Authors:  Charles Burdet; Nathalie Grall; Morgane Linard; Antoine Bridier-Nahmias; Michèle Benhayoun; Khadija Bourabha; Mélanie Magnan; Olivier Clermont; Camille d'Humières; Olivier Tenaillon; Erick Denamur; Laurent Massias; Sarah Tubiana; Loubna Alavoine; Antoine Andremont; France Mentré; Xavier Duval
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Pharmacokinetics of cefoperazone in the parturient.

Authors:  B Gonik; S Feldman; L K Pickering; C G Doughtie
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 4.  Cefoperazone prevents the inactivation of alpha(1)-antitrypsin by activated neutrophils.

Authors:  F Dallegri; P Dapino; N Arduino; M Bertolotto; L Ottonello
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

5.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 6.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

8.  Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

Authors:  A M Brisson; A Bryskier; L Millerioux; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Pharmacokinetics and quantitative characterization of cefotiam excretion after intravenous administration to patients after cholecystectomy.

Authors:  D Terziivanov; Z Gerova; V Vlahov; A Merdzhanov; D Damjanov
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules.

Authors:  A Heikkilä; R Erkkola
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.